Protagonist Therapeutics, Inc PTGX
Protagonist Therapeutics, Inc (Nasdaq: PTGX) is an immunology/inflammation drug developer. Its lead program, PN-881, is in Phase 1 for Immune-mediated skin diseases, plaque psoriasis (oral IL-17 antagonist peptide). Its next catalyst on record is PN-881: Initiation of Phase 2b psoriasis program (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: PN-881 — Initiation of Phase 2b psoriasis program (Q1 2027). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| PN-881 | Plaque psoriasis, PsA, HS, spondyloarthritis (oral IL-17 antagonist; Phase 1 healthy adults, first dosed Oct 2025) | protein/peptide | Phase 1 |
| PN-477sc | Obesity (triple GLP-1/GIP/GCG agonist, subcutaneous; Phase 1 initiated) | protein/peptide | Phase 1 |
| PN-477o | Obesity (oral triple agonist) | protein/peptide | Pre-clinical |
| PN-458 | Obesity (dual GLP-1/GIP agonist; IND-enabling) | protein/peptide | Pre-clinical |
| PN-8047 | Polycythemia vera (oral small-molecule hepcidin mimetic; IND-enabling) | small molecule | Pre-clinical |
| Oral IL-4R alpha antagonist | Atopic dermatitis, asthma | protein/peptide | Pre-clinical |
| AmylinR-based mono/poly-agonists | Obesity | protein/peptide | Pre-clinical |
Recent results and decisions
- Aug 5, 2026positive EMA CHMP positive opinion for icotrokinra (July 2026) shown on corporate deck timeline.
July ’26 EMA CHMP Positive Opinion
Filing - May 5, 2026approval FDA approved ICOTYDE (icotrokinra) on March 18, 2026 for adults and adolescents 12+ with plaque psoriasis (partner J&J), triggering a $50M milestone.
On March 18, Protagonist announced that Johnson & Johnson received U.S. Food and Drug Administration approval for ICOTYDE for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg and are candidates for systemic thera
Filing - May 5, 2026accepted FDA accepted rusfertide NDA with Priority Review on March 2, 2026; PDUFA goal date August 2026.
The FDA set a PDUFA goal date in August 2026.
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.